Roche and Evotec end depression alliance as Phase II trial proves 'too difficult'
This article was originally published in Scrip
Executive Summary
Roche and Evotec have decided to terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT101 and halt its clinical development.